MedTrace Logo

Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

NCT04175262 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2023-05-03

Study results available
· View outcomes & findings →

Summary

The study aims to assess clinical outcomes in mRCC patients treated with sunitinib in second-line following IO therapy in real world clinical practices.

Conditions

  • Metastatic Renal Cell Carcinoma (mRCC)

Interventions

DRUG

sunitinib

Patients to receive sunitinib as second line therapy for mRCC

Sponsors & Collaborators

  • International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)

    collaborator OTHER

  • Analysis Group, Inc.

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2020-03-09
Completion
2020-03-09

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04175262 on ClinicalTrials.gov